Use and prescribing patterns for erythropoiesis-stimulating agents in inpatient and outpatient hospital settings

American Journal of Health-System Pharmacy

Volumn 65, Issue 18, 2008, Pages 1711-1719

  Siegel, Jerry ^a   Jorgenson, James ^b   Johnson, Philip E ^c   Brophy, Donald F ^d   Comstock, Thomas ^e   Feng, Amy ^e   Audhya, Paul ^e  

^a THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

^b UNIVERSITY OF UTAH HOSPITAL   (United States)

^c H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^d VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e AMGEN INC   (United States)

Author keywords

Anemia; Darbepoetin alfa; Dosage schedules; Drug use; Epoetin alfa; Hematopoietic agents; Hospitals; Prescribing

Indexed keywords

ANTINEOPLASTIC AGENT; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RECOMBINANT ERYTHROPOIETIN;

ANEMIA; ARTICLE; CANCER CENTER; CHEMOTHERAPY INDUCED ANEMIA; DIALYSIS; DOSAGE SCHEDULE COMPARISON; DRUG INDICATION; HOSPITAL PATIENT; HOSPITAL PHARMACY; HUMAN; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MEDICAL SPECIALIST; OUTPATIENT; PHARMACIST; PRESCRIPTION; PRIORITY JOURNAL;

EID: 52949091958     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.2146/ajhp070526     Document Type: Article

References (20)

1. Tong EM, Nissenson AR. Erythropoietin and anemia. Semin Nephrol. 2001; 21:190-203.
2. Macdougall IC. Novel erythropoiesis stimulating protein. Semin Nephrol. 2000; 20:375-81.
3. Elliott S, Lorenzini T, Asher S et al. Enhancement of therapeutic protein in vivo activities through glycoengineering. Nat Biotechnol. 2003; 21:414-21.
4. Egrie JC, Dwyer E, Browne JK et al. Darbepoetin alfa has a longer circulating half-life and greater in vivo potency than recombinant human erythropoietin. Exp Hematol. 2003; 31:290-9.
5. Eschbach JW, Abdulhadi MH, Browne JK et al. Recombinant human erythropoietin in anemic patients with end-stage renal disease. Results of a phase III multicenter clinical trial. Ann Intern Med. 1989; 111:992-1000.
6. Nissenson AR, Korbet S, Faber M et al. Multicenter trial of erythropoietin in patients on peritoneal dialysis. J Am Soc Nephrol. 1995; 5:1517-29.
7. Epogen (epoetin alfa) prescribing information. Thousand Oaks, CA: Amgen Inc.; 2007 Mar.
8. Procrit (epoetin alfa) prescribing information. Raritan, NJ: Ortho Biotech Products, L.P.; 2007 Nov.
9. National kidney foundation. K/DOQI clinical practice guidelines for chronic disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002; 39(suppl 1):S1-266.
10. Aranesp (darbepoetin alfa) prescribing information. Thousand Oaks, CA: Amgen Inc.; 2007 Nov.
11. Association of American Medical Colleges. Council of Teaching Hospitals and Health Systems. www.aamc.org/members/coth (accessed 2008 Jul 17).
12. Patkar A, Holdfold D, Brophy DF et al. Off-label prescribing of erythropoiesis-stimulating proteins in US hospitals. Drug Information J. 2007; 41:431-40.
13. Bileneker JH, Demers R, Porter DL et al. Recombinant human erythropoietin usage in a large academic medical center. Am J Manag Care. 2002; 8:742-7.
14. Lacson E Jr, Ofsthun N, Lazarus JM. Effect of variability in anemia management on hemoglobin outcomes in ESRD. Am J Kidney Dis. 2003; 41:111-24.
15. Grabe DW. Update on clinical practice recommendations and new therapeutic modalities for treating anemia in patients with chronic kidney disease. Am J Health-Syst Pharm. 2007; 64(suppl 12):S8-14.
16. Pronzato P. Cancer-related anaemia management in the 21st century. Cancer Treat Rev. 2006; 32(suppl 2):S1-3.
17. Parmenter M, Comstock T, Barlev A. Opportunities created by JCAHO patient safety goal for documentation of current medications: a model of the benefits of extended outpatient dosing. Presented at ASHP Midyear Clinical Meeting. Anaheim, CA; 2006 Dec.
18. Von Ahsen N, Muller C, Serke S et al. Important role of nondiagnostic blood loss and blunted erythropoietic response in the anemia of medical intensive care patients. Crit Care Med. 1999; 27:2630-9.
19. Yaqub MS, Lieser J, Molitoris BA. Erythropoietin requirements increase following hospitalization in end-stage renal disease patients. Am J Nephrol. 2001; 21:390-6.
20. Joint Commission. 2007 Hospital/critical access hospital national patient safety goals. www.jointcommission.org/PatientSafety/NationalPatientSafetyGoals/ 07_hap_cah_npsgs.htm (accessed 2007 Jul).